Richtlijnen
Klik HIER voor de behandelrichtlijn AML (2021) van de HOVON Leukemie werkgroep.
Klik HIER voor het consensus document MRD bij AML (2018) van de ELN MRD werkgroep.
Literatuur
- Schuurhuis GJ et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131(12): 1275-1291. doi: 10.1182/blood-2017-09-801498
- Terwijn M et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013; 31(31): 3889-3897. e-pub ahead of print 2013/09/26; doi: 10.1200/JCO.2012.45.9628
- Zeijlemaker W et al. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia. Leukemia 2016; 30(3): 708-715. e-pub ahead of print 2015/09/17; doi: 10.1038/leu.2015.255
- Ivey A et al. Assessment of Minimal Residual Disease in Standard-Risk AML. The New England journal of medicine 2016. doi: 10.1056/NEJMoa1507471
- Ehinger M, Pettersson L. Measurable residual disease testing for personalized treatment of acute myeloid leukemia. APMIS 2019. e-pub ahead of print 2019/03/29; doi: 10.1111/apm.12926
- Wang Y et al. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood 2014; 124(12): 1880-1886. e-pub ahead of print 2014/08/02; doi: 10.1182/blood-2014-03-563403
- Döhner H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 129:424-447
- Arber D.A. et al. The 2016 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 127:2391-2405
- Sorror M.L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005 106: 2912-2919
Ga terug naar de AML homepage of lees meer over AML:
- Diagnostiek
- Classificatie
- Risicoclassificatie
- Behandeling
- Respons criteria
- MRD
- Beheer en wijzigingenhistorie
Ga terug naar de algemene homepage Behandelprotocollen.